

PATENT Attorney Docket 060616-5003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ian Duncan Rubin et al.) Group Art Unit: 1655
Application No. 09/891,615	Examiner: Michele C. Flood
Filed: June 27, 2001) Allowed: July 13, 2005
For: Extracts, Compounds and Pharmaceutical Compositions Having Anti-Diabetic Activity and Their Use (as amended)) Confirmation No. 8850


COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

In response to the Examiner's Statement of Reasons for Allowance in the Notice of Allowability dated July 13, 2005, the following comments are submitted under 37 C.F.R. 1.104(e).

While Applicants believe that the claims are allowable and patentably distinguishable over the prior art, Applicants do not acquiesce that patentability resides in each feature, exactly as expressed in the claims, nor that each and every feature is required for patentability. Applicants submit that patentability is based on the claimed invention as a whole, and not solely on one or more particular features recited in the allowed claims.

Dated: October 13, 2005 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 202-739-3000 Respectfully submitted,
Morgan, Lewis & Bockius LLP

Registration No. 46,882



PATENT Attorney Docket 060616-5003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ian Duncan Rubin et al.) Group Art Unit: 1655
Application No. 09/891,615) Examiner: Michele C. Flood
Filed: June 27, 2001) Allowed: July 13, 2005
For: Extracts, Compounds and Pharmaceutical Compositions Having Anti-Diabetic Activity and Their Use (as amended)) Confirmation No. 8850)
U.S. Patent and Trademark Office Customer Service Window, Mail Stop Issue Fee Randolph Building 401 Dulany Street Alexandria, VA 22314	

TRANSMITTAL FORM

- 1. Transmitted herewith is the Issue Fee Transmittal (PTOL-85B).
- 2. Additional Papers Submitted:
 - (i) Comments on Statement of Reasons for Allowance
- 3. <u>Fee Payment</u>: The Commissioner is hereby authorized to charge \$1,709.00 to Deposit Account No. 50-0310 for payment of the Issue Fee (\$1,400.00), the publication fee (\$300.00) and advance order of three soft copies of the issued patent (\$9.00).
- 4. Constructive Petition: Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a constructive petition for extension of time in accordance with 37 C.F.R. 1.136(a)(3).

Dated: October 13, 2005 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004

Tel: 202-739-3000 Fax: 202-739-3001 Respectfully submitted,
Morgan, Lewis & Bockius LLP

Gregory T. Lowen, Ph.D. Registration No. 46,882 Tel: 202-739-5915